8-K: Quoin Pharmaceuticals Announces 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing

Quoin Pharmaceuticals is implementing a 1-for-20 reverse stock split of its American Depositary Shares (ADSs) to meet Nasdaq's minimum bid price requirement.

Summary

• Quoin Pharmaceuticals has announced a 1-for-20 reverse stock split of its American Depositary Shares (ADSs).
• The reverse split is intended to increase the per share market price of the company's ADSs to comply with Nasdaq's $1.00 minimum bid price requirement.
• The reverse split will be effective at the opening of the market on April 8, 2025.
• The company's ordinary shares will not be affected by this adjustment.
• The new CUSIP number for the ADS following the Ratio Change will be 74907L409.
• Holders of uncertificated ADSs in DRS and DTC do not need to take any action as the exchange will occur automatically.
• Registered holders of certificated ADSs will need to surrender their certificates to the depositary bank to receive new ADSs.

Sentiment

Score: 4

Explanation: The announcement of a reverse stock split is generally viewed negatively by investors as it indicates the company's share price has fallen below acceptable levels. While the company is taking action to address the issue, the outcome is uncertain.

Positives

• The reverse stock split is a proactive measure to maintain the company's listing on The Nasdaq Capital Market.

Negatives

• The company acknowledges that there is no guarantee the reverse stock split will result in satisfying and maintaining the minimum bid price requirement of Nasdaq.

Risks

• There is a risk that the reverse stock split may not be sufficient to maintain compliance with Nasdaq's minimum bid price requirement.
• Failure to maintain Nasdaq listing could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

The company hopes that the reverse stock split will allow it to maintain its Nasdaq listing, but there is no guarantee.

Management Comments

• The objective of the Ratio Change is to increase the per share market price of the Company's ADSs to comply with Nasdaq's $1.00 minimum bid price per share requirement and maintain the Company's listing on The Nasdaq Capital Market.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices. Other companies in the pharmaceutical industry that have undertaken similar actions include companies such as BioPharmX and Diffusion Pharmaceuticals.

Comparison to Industry Standards

• Reverse stock splits are a relatively common tool used by companies, particularly in the biotech and pharmaceutical sectors, to maintain listing compliance.
• For example, Diffusion Pharmaceuticals recently implemented a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
• BioPharmX also executed a reverse stock split for similar reasons.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they hold, but the proportional ownership will remain the same.
• The reverse stock split could impact investor confidence and trading liquidity.

Key Dates

Keywords

reverse stock split, ADS, Nasdaq, minimum bid price, QNRX, Quoin Pharmaceuticals, listing compliance